文献速递膀胱癌与上尿路尿路上皮癌

膀胱内注射度伐利尤单抗治疗高危非肌层浸润性膀胱癌:希腊泌尿生殖肿瘤协作组的一项2期研究

Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
PubMed 文献 · Eur Urol · 2025-01-17

这项单臂2期研究纳入30例卡介苗治疗失败的高危非肌层浸润性膀胱癌患者,每6周膀胱内给予度伐利尤单抗,导入期最大耐受剂量为1000 mg。完成治疗后1年高级别复发无生存率为39%(95%CI 18-59%),1年膀胱完整生存率为78%(95%CI 57-89%),唯一治疗相关不良事件为5例(17%)1级血尿。

要点

  • 卡介苗失败高危NMIBC患者每6周膀胱内度伐利尤单抗1000 mg可行,毒性可忽略。
  • 完成治疗后1年高级别复发无生存率39%(95%CI 18-59%)。
  • 1年膀胱完整生存率78%(95%CI 57-89%),作者认为值得进一步研究。

核心结论

  • 卡介苗失败高危NMIBC患者每6周膀胱内度伐利尤单抗1000 mg可行,毒性可忽略且疗效令人鼓舞。
  • 膀胱内度伐利尤单抗可能比全身给药免疫检查点抑制剂更有吸引力,值得进一步研究作为NMIBC的治疗。

研究设计与样本

  • 单臂2期研究,纳入30例卡介苗治疗失败的高危非肌层浸润性膀胱癌患者。
  • 导入期确定最大耐受剂量为1000 mg,2期每6周膀胱内给予度伐利尤单抗。
  • 试验在ClinicalTrials.gov注册号为NCT03759496。

主要发现

  • 完成治疗后1年高级别复发无生存率为39%(95%CI 18-59%)。
  • 完成研究治疗后1、3、6个月高级别复发无生存率分别为70%(95%CI 45-85%)、55%(95%CI 31-74%)、39%(95%CI 18-59%)。
  • 完成入组后13个月,2期有4例患者进展至≥T2期;1年膀胱完整生存率为78%(95%CI 57-89%)。
  • 唯一治疗相关不良事件为5例(17%)1级血尿。

关键数值与推荐

  • 导入期最大耐受剂量为1000 mg。
  • 2期给药方案为每6周膀胱内度伐利尤单抗。
  • 完成治疗后1年高级别复发无生存率39%(95%CI 18-59%)。
  • 1年膀胱完整生存率78%(95%CI 57-89%)。

临床怎么用

  • 作者认为膀胱内度伐利尤单抗1000 mg每6周在卡介苗失败高危NMIBC患者中可行,毒性可忽略且疗效令人鼓舞。
  • 作者认为膀胱内度伐利尤单抗可能比全身给药免疫检查点抑制剂更有吸引力,值得进一步研究作为NMIBC的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for whom bacillus Calmette-Guérin (BCG) treatment has failed, bladder preservation is a high priority. Immune checkpoint inhibitors have shown promise, but systemic administration is associated with substantial toxicity. In this single-arm phase 2 study, 30 patients with NMIBC after BCG failure were treated with intravesical durvalumab every 6 wk. The maximum tolerated dose in the run-in phase was 1000 mg. In phase 2, the high-grade relapse (HGR)-free rate at 1 yr after completing therapy was 39% (95% confidence interval [CI] 18-59%). HGR-free rates at 1, 3, and 6 mo after completing study treatment were 70% (95% CI 45-85%), 55% (95% CI 31-74%), and 39% (95% CI 18-59%), respectively. At 13 mo after completing enrolment, four patients in phase 2 had experienced progression to stage ≥T2; the 1-yr bladder-intact survival rate was 78% (95% CI 57-89%). The only treatment-related adverse event was grade 1 haematuria in five patients (17%). In conclusion, intravesical durvalumab 1000 mg every 6 wk is feasible after BCG failure in patients with high-risk NMIBC, with negligible toxicity and encouraging efficacy. Intravesical durvalumab may be more attractive than systemic administration of immune checkpoint inhibitors and warrants further investigation as a treatment for NMIBC. This trial is registered on ClinicalTrials.gov as NCT03759496.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Fragkoulis C, Bamias A, Gavalas N, et al. Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group. Eur Urol. 2025. PMID: 39827021. doi:10.1016/j.eururo.2024.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。